Skip to content

Doctors and patients are flying blind as medical marijuana use rises, research lags

July 25, 2019 / Arfinn Med MD /

Doctors and patients are flying blind as medical marijuana use rises, research lags

Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to treat health issues like rheumatic and musculoskeletal disease (the aches and pains of arthritis).

Unfortunately, because cannabis remains illegal and classified as a Schedule 1 drugunder federal law (defined as being of no medical use), there has been a troubling lack of scientific and medical research on the effectiveness of cannabis treatments. This dearth of evidence-based data has left many health care providers unable to counsel their patients on everything from whether a cannabis treatment could be effective for their condition, to what dosages are appropriate, to how cannabis might interact with their other medications or health conditions.

Read Full Article Here

Stories you may be interested in

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More →

Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says

Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020. Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber…
Read More →

State Board of Health reviews timelines for establishing Mississippi medical marijuana program

JACKSON, Miss. (WLBT) – The blueprint for Mississippi’s medical marijuana program is Initiative 65 that voters approved in November. That contains detailed requirements and the clock is ticking to get it started. The State Board of Health met virtually Wednesday to discuss the groundwork of the medical marijuana program. “I do want to tell you…
Read More →

Former Detroit Lions players announce partnership with Harvard to study marijuana

Former Detroit Lions football players Calvin Johnson and Robert Sims are expanding their emerging cannabis enterprise into the field of medicine. The pair announced an agreement Thursday with the International Phytomedicines and Medical Cannabis Institute at Harvard University, which is researching the benefits of medical marijuana and looking at the best ways to deliver cannabis-based…
Read More →

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More →

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More →

Leave a Comment

You must be logged in to post a comment.